“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey-Reference-Cited by-同舟云学术

“Real‐world” eligibility for aducanumab depends on clinical setting and patients' journey

Published:2021-11-09 Issue:2 Volume:70 Page:626-628
ISSN:0002-8614
Container-title:Journal of the American Geriatrics Society
language:en
Short-container-title:J American Geriatrics Society

Author:

Padovani Alessandro¹²^ORCID,Caratozzolo Salvatore²,Rozzini Luca¹²,Pilotto Andrea¹²^ORCID,Benussi Alberto¹²,Tedeschi Gioacchino³

Affiliation:

1. Neurology Unit, Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

2. Neurology Unit, Department of Neurological and Vision Sciences ASST Spedali Civili Brescia Italy

3. Neurology Unit, Department of Advanced Medical and Surgical Sciences University of Campania "Luigi Vanvitelli" Naples Italy

Publisher

Wiley

Subject

Geriatrics and Gerontology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.17530

Reference12 articles.

1. Alzheimer's disease: a time for cautious optimism;The Lancet Neurology;Lancet Neurol,2015

2. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer's treatment;Hlavka JP;Rand Health Q,2019

3. The Italian Dementia National Plan;Di Fiandra T;Ann Ist Super Sanita,2015

4. Italian consensus recommendations for a biomarker‐based aetiological diagnosis in mild cognitive impairment patients

5. How many patients are eligible for disease‐modifying treatment in Alzheimer's disease? A French national observational study over 5 years;Epelbaum S;BMJ Open,2019

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for emergency departments: Anti‐amyloid therapy and amyloid‐related imaging abnormalities in persons with dementia;Journal of the American Geriatrics Society;2024-07-22

2. Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease;Journal of Neurology, Neurosurgery & Psychiatry;2024-06-11

3. Validation and Convergent Validity of the Boston Cognitive Assessment (BOCA) in an Italian Population: A Comparative Study with the Montreal Cognitive Assessment (MoCA) in Alzheimer’s Disease Spectrum;2024-05-06

4. Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer’s disease to individuals with MCI or early AD in the general population;2024-02-29

5. Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort;Journal of Neurology;2024-02-21